Personal Injury Lawyers
Menu
602.252.8888
800.883.8888
Attorney Jon O'Steen

Attorney for Testosterone Therapy Drug Patients Urges FDA to Prevent "Off Label" Use of Medications

Jonathan V. O'Steen

July 30, 2014

Share |

Phoenix, Arizona—Phoenix Attorney Jonathan O’Steen has asked the federal Food and Drug Administration (FDA) to take action to prevent off-label use of the testosterone therapy drugs AndroGel, AndroDerm, Axiron, Bio-T-Gel, Delatestryl, Depo-Testosterone, Fortesta, Striant, Testim, or Testopel.

“Off-label use” is a term that applies to the practice of prescribing a drug for uses, time periods or dosages that have not been approved by the FDA.

In a letter to the FDA dated July 30, 2014, O’Steen wrote that FDA approval of the testosterone medications was limited to “men properly diagnosed with the medical condition hypogonadism.” Instead, O’Steen wrote that “these drugs are widely prescribed ‘off label’ to men who are experiencing only natural age-related reductions in testosterone production.”

O’Steen noted that pharmaceutical company advertising aimed at consumers variously claim that testosterone therapy drugs will produce increased muscle growth, reduced body fat, enhanced energy levels, improved sex drive and performance, and stronger bones.

“Medical research reveals, however, that men who use these drugs are at a substantially increased risk of heart attack, stroke and death,” O’Steen added.

O’Steen requested that the FDA act now to prevent further off label use of testosterone therapy drugs during the pendency of its current investigation.

Resources

Letter from Jonathan V. O’Steen to the U.S. Food and Drug Administration, re: Testosterone Therapy Drugs (July 30, 2014)

Testosterone Products: Drug Safety Communication – FDA Investigating Risk of Cardiovascular Events,U.S. Food and Drug Administration (January 31, 2014)

Global trends in testosterone prescribing, 2000-2011: expanding the spectrum of prescription drug misuse, The Medical Journal of Australia (August 2013)

About O’Steen & Harrison, PLC

O’Steen & Harrison, PLC has protected the rights of injured accident victims and their family members since 1974. The firm concentrates on personal injury, medical malpractice and dangerous products including harmful drugs, defective medical devices and contaminated food products. O’Steen & Harrison is av-rated (the highest rating) by the prestigious Martindale-Hubbell Law Directory.

The firm’s attorneys have recovered more than $3 billion dollars for clients. O’Steen & Harrison offers free, confidential consultations to anyone who has been injured by a dangerous product. Call toll free 1-800-883-8888 or see our web site at www.vanosteen.com.

Contact

Jonathan V. O’Steen
O’Steen & Harrison, PLC
602-252-8888
josteen@vanosteen.com

Testosterone Therapy News

Low-T Drug Lawsuits Grow in Number

More than 150 lawsuits already have been filed against manufacturers of low testosterone therapy drugs in the U.S. District Court for Northern District of Illinois.

Attorney Urges FDA to Prevent Off Label Use of Testosterone Therapy Drugs

Phoenix attorney Jonathan O'Steen has asked the FDA to take action to prevent off-label use of testosterone therapy drugs.

AndroGel Manufacturer Wants Coordination of Testosterone Lawsuits

In June, all testosterone therapy lawsuits previously filed in various courts throughout the United States were consolidated in a single court—the U.S. District Court for the Northern District of Illinois. Testosterone Therapy Lawsuit